Skip to main content

Cardiovascular outcomes


11-23-2017 | Cardiovascular outcomes | News

Intensive diabetes treatment reduces CVD risk even with excessive weight gain

Intensive treatment of type 1 diabetes appears to reduce the risk for cardiovascular disease events even in those who gain excessive weight, but improved management of cardiovascular risk factors and revascularization may be needed.

11-14-2017 | Canagliflozin | News

Canagliflozin benefits may extend to primary prevention

Further analysis of the CANVAS trial suggests that the benefits of canagliflozin treatment are broadly consistent in type 2 diabetes patients with and without pre-existing cardiovascular disease,

11-13-2017 | Older adults | News

CV complications impact survival in elderly type 2 diabetes patients

Cardiovascular complications, and heart failure in particular, are strongly associated with poor survival in elderly patients with type 2 diabetes, French observational study data show.

Read more


11-22-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

11-13-2017 | Specific populations | Interview | Video

Women and diabetes - our right to a healthy future

Editorial Board member Lori Berard addresses 2017's World Diabetes Day theme, providing her insights on the key considerations for managing diabetes in women in this interview with Medicine Matters diabetes.

10-23-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Glucagon-like peptide-1 receptor agonist use in acute myocardial infarction

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.

In depth

10-17-2017 | Glucagon-like peptide-1 agonists | Feature | Article

GLP-1 receptor agonists: Cardiovascular trials and triumphs

With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.

08-22-2017 | Canagliflozin | Podcast | Audio

Dissecting the CANVAS trial

Listen to editorial board members and CANVAS investigators Carol Wysham and Lori Berard discussing the efficacy and safety findings of the trials.

Journal articles and book chapters

10-11-2017 | Cardiovascular disorders | Review | Article

Updates on cardiovascular outcome trials in diabetes

This review summarizes the results of the DEVOTE, CANVAS, EXSCEL, and ACE trials that tested the cardiovascular safety of insulin degludec, canagliflozin, once-weekly exenatide, and acarbose, respectively.

Schnell O et al. Cardiovasc Diabetol 2017;16:128. doi:10.1186/s12933-017-0610-y

07-19-2017 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome trial update in diabetes: New evidence, remaining qestions

Seven trials of antihyperglycemic agents from different classes have now been concluded as of May 2017. This review summarizes, compares, and contrasts the key cardiovascular (CV) and non-CV findings from these trials.

Herbst R, Bolton W, Shariff A, Green JB. Curr Diab Rep 2017;17:67. doi:10.1007/s11892-017-0898-8

02-02-2017 | Cardiovascular outcomes | Review | Article

Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

Many of the currently available oral anti-diabetic agents have clinically relevant cardiovascular effects. This expert review concludes that optimal approach to the reduction of cardiovascular risk in diabetic patients should focus on aggressive management of the standard cardiovascular risk factors rather than purely on intensive glycemic control.

Xu J & Rajaratnam R. Cardiovasc Diabetol 2017;16:18. doi:10.1186/s12933-017-0499-5

image credits